Follow up and comparative assessment of IgG, IgA, and neutralizing antibody responses to SARS-CoV-2 between mRNA-vaccinated naïve and unvaccinated naturally infected individuals over 10 months

<h3>Background</h3><p dir="ltr">Evidence on the effectiveness of vaccination-induced immunity compared to SARS-CoV-2 natural immunity is warranted to inform vaccination recommendations.</p><p><br></p><h3>Aim</h3><p dir="ltr"...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلف الرئيسي: Salma Younes (6424865) (author)
مؤلفون آخرون: Eleonora Nicolai (496034) (author), Duaa W. Al-Sadeq (10976754) (author), Nadin Younes (4863280) (author), Nader Al-Dewik (4166527) (author), Haissam Abou-Saleh (497840) (author), Bushra Y. Abo-Halawa (17863883) (author), Ali Hussein Eid (13355211) (author), Massimo Pieri (5023022) (author), Na Liu (102929) (author), Hanin I. Daas (17863886) (author), Hadi M. Yassine (4675846) (author), Parveen B. Nizamuddin (14590613) (author), Laith J. Abu-Raddad (9262524) (author), Gheyath K. Nasrallah (9200525) (author)
منشور في: 2023
الموضوعات:
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
_version_ 1864513528846614528
author Salma Younes (6424865)
author2 Eleonora Nicolai (496034)
Duaa W. Al-Sadeq (10976754)
Nadin Younes (4863280)
Nader Al-Dewik (4166527)
Haissam Abou-Saleh (497840)
Bushra Y. Abo-Halawa (17863883)
Ali Hussein Eid (13355211)
Massimo Pieri (5023022)
Na Liu (102929)
Hanin I. Daas (17863886)
Hadi M. Yassine (4675846)
Parveen B. Nizamuddin (14590613)
Laith J. Abu-Raddad (9262524)
Gheyath K. Nasrallah (9200525)
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author_facet Salma Younes (6424865)
Eleonora Nicolai (496034)
Duaa W. Al-Sadeq (10976754)
Nadin Younes (4863280)
Nader Al-Dewik (4166527)
Haissam Abou-Saleh (497840)
Bushra Y. Abo-Halawa (17863883)
Ali Hussein Eid (13355211)
Massimo Pieri (5023022)
Na Liu (102929)
Hanin I. Daas (17863886)
Hadi M. Yassine (4675846)
Parveen B. Nizamuddin (14590613)
Laith J. Abu-Raddad (9262524)
Gheyath K. Nasrallah (9200525)
author_role author
dc.creator.none.fl_str_mv Salma Younes (6424865)
Eleonora Nicolai (496034)
Duaa W. Al-Sadeq (10976754)
Nadin Younes (4863280)
Nader Al-Dewik (4166527)
Haissam Abou-Saleh (497840)
Bushra Y. Abo-Halawa (17863883)
Ali Hussein Eid (13355211)
Massimo Pieri (5023022)
Na Liu (102929)
Hanin I. Daas (17863886)
Hadi M. Yassine (4675846)
Parveen B. Nizamuddin (14590613)
Laith J. Abu-Raddad (9262524)
Gheyath K. Nasrallah (9200525)
dc.date.none.fl_str_mv 2023-11-01T00:00:00Z
dc.identifier.none.fl_str_mv 10.1016/j.jiph.2023.08.009
dc.relation.none.fl_str_mv https://figshare.com/articles/journal_contribution/Follow_up_and_comparative_assessment_of_IgG_IgA_and_neutralizing_antibody_responses_to_SARS-CoV-2_between_mRNA-vaccinated_na_ve_and_unvaccinated_naturally_infected_individuals_over_10_months/25101905
dc.rights.none.fl_str_mv CC BY 4.0
info:eu-repo/semantics/openAccess
dc.subject.none.fl_str_mv Biomedical and clinical sciences
Clinical sciences
COVID-19
MRNA vaccines
Waning
Neutralizing antibodies
Anti-S-RBD-IgG
Anti-S1-IgA
dc.title.none.fl_str_mv Follow up and comparative assessment of IgG, IgA, and neutralizing antibody responses to SARS-CoV-2 between mRNA-vaccinated naïve and unvaccinated naturally infected individuals over 10 months
dc.type.none.fl_str_mv Text
Journal contribution
info:eu-repo/semantics/publishedVersion
text
contribution to journal
description <h3>Background</h3><p dir="ltr">Evidence on the effectiveness of vaccination-induced immunity compared to SARS-CoV-2 natural immunity is warranted to inform vaccination recommendations.</p><p><br></p><h3>Aim</h3><p dir="ltr">In this study, we aimed to conduct a comparative assessment of antibody responses between vaccinated naïve (VN) and unvaccinated naturally infected individuals (NI) over 10 Months.</p><p><br></p><h3>Method</h3><p dir="ltr">The study comprised fully-vaccinated naïve individuals (VN; n = 596) who had no history of SARS-CoV-2 infection, and received two doses of either BNT162b2 or mRNA-1273, and naturally infected individuals who had a documented history of SARS-CoV-2 infection and no vaccination record (NI cohort; n = 218). We measured the levels of neutralizing total antibodies (NtAbs), anti-S-RBD IgG, and anti-S1 IgA titers among VN and NI up to ∼10 months from administration of the first dose, and up to ∼7 months from SARS-CoV-2 infection, respectively. To explore the relationship between the antibody responses and time, Spearman's correlation coefficient was computed. Furthermore, correlations between the levels of NtAbs/anti-S-RBD IgG and NtAbs/anti-S1 IgA were examined through pairwise correlation analysis.</p><p><br></p><h3>Results</h3><p dir="ltr">Up to six months, VN individuals had a significantly higher NtAb and anti-S-RBD IgG antibody responses compared to NI individuals. At the 7th month, there was a significant decline in antibody responses among VN individuals, but not NI individuals, with a minimum decrease of 3.7-fold (p < 0.001). Among VN individuals, anti-S1 IgA levels began to decrease significantly (1.4-fold; p = 0.007) after two months, and both NtAb and S-RBD IgG levels began to decline significantly (NtAb: 2.0-fold; p = 0.042, S-RBD IgG: 2.4-fold; p = 0.035) after three months. After 10 months, the most significant decline among VN individuals was observed for S-RBD-IgG (30.0-fold; P < 0.001), followed by NtAb (15.7-fold; P < 0.001) and S-IgA (3.7-fold; P < 0.001) (most stable). Moreover, after 5 months, there was no significant difference in the IgA response between the two groups.</p><p><br></p><h3>Conclusion</h3><p dir="ltr">These findings have important implications for policymakers in the development of vaccination strategies, particularly in the consideration of booster doses to sustain long-lasting protection against COVID-19.</p><h2>Other Information</h2><p dir="ltr">Published in: Journal of Infection and Public Health<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.jiph.2023.08.009" target="_blank">https://dx.doi.org/10.1016/j.jiph.2023.08.009</a></p>
eu_rights_str_mv openAccess
id Manara2_ed8ce6f3b384c4e827d687f21b92401e
identifier_str_mv 10.1016/j.jiph.2023.08.009
network_acronym_str Manara2
network_name_str Manara2
oai_identifier_str oai:figshare.com:article/25101905
publishDate 2023
repository.mail.fl_str_mv
repository.name.fl_str_mv
repository_id_str
rights_invalid_str_mv CC BY 4.0
spelling Follow up and comparative assessment of IgG, IgA, and neutralizing antibody responses to SARS-CoV-2 between mRNA-vaccinated naïve and unvaccinated naturally infected individuals over 10 monthsSalma Younes (6424865)Eleonora Nicolai (496034)Duaa W. Al-Sadeq (10976754)Nadin Younes (4863280)Nader Al-Dewik (4166527)Haissam Abou-Saleh (497840)Bushra Y. Abo-Halawa (17863883)Ali Hussein Eid (13355211)Massimo Pieri (5023022)Na Liu (102929)Hanin I. Daas (17863886)Hadi M. Yassine (4675846)Parveen B. Nizamuddin (14590613)Laith J. Abu-Raddad (9262524)Gheyath K. Nasrallah (9200525)Biomedical and clinical sciencesClinical sciencesCOVID-19MRNA vaccinesWaningNeutralizing antibodiesAnti-S-RBD-IgGAnti-S1-IgA<h3>Background</h3><p dir="ltr">Evidence on the effectiveness of vaccination-induced immunity compared to SARS-CoV-2 natural immunity is warranted to inform vaccination recommendations.</p><p><br></p><h3>Aim</h3><p dir="ltr">In this study, we aimed to conduct a comparative assessment of antibody responses between vaccinated naïve (VN) and unvaccinated naturally infected individuals (NI) over 10 Months.</p><p><br></p><h3>Method</h3><p dir="ltr">The study comprised fully-vaccinated naïve individuals (VN; n = 596) who had no history of SARS-CoV-2 infection, and received two doses of either BNT162b2 or mRNA-1273, and naturally infected individuals who had a documented history of SARS-CoV-2 infection and no vaccination record (NI cohort; n = 218). We measured the levels of neutralizing total antibodies (NtAbs), anti-S-RBD IgG, and anti-S1 IgA titers among VN and NI up to ∼10 months from administration of the first dose, and up to ∼7 months from SARS-CoV-2 infection, respectively. To explore the relationship between the antibody responses and time, Spearman's correlation coefficient was computed. Furthermore, correlations between the levels of NtAbs/anti-S-RBD IgG and NtAbs/anti-S1 IgA were examined through pairwise correlation analysis.</p><p><br></p><h3>Results</h3><p dir="ltr">Up to six months, VN individuals had a significantly higher NtAb and anti-S-RBD IgG antibody responses compared to NI individuals. At the 7th month, there was a significant decline in antibody responses among VN individuals, but not NI individuals, with a minimum decrease of 3.7-fold (p < 0.001). Among VN individuals, anti-S1 IgA levels began to decrease significantly (1.4-fold; p = 0.007) after two months, and both NtAb and S-RBD IgG levels began to decline significantly (NtAb: 2.0-fold; p = 0.042, S-RBD IgG: 2.4-fold; p = 0.035) after three months. After 10 months, the most significant decline among VN individuals was observed for S-RBD-IgG (30.0-fold; P < 0.001), followed by NtAb (15.7-fold; P < 0.001) and S-IgA (3.7-fold; P < 0.001) (most stable). Moreover, after 5 months, there was no significant difference in the IgA response between the two groups.</p><p><br></p><h3>Conclusion</h3><p dir="ltr">These findings have important implications for policymakers in the development of vaccination strategies, particularly in the consideration of booster doses to sustain long-lasting protection against COVID-19.</p><h2>Other Information</h2><p dir="ltr">Published in: Journal of Infection and Public Health<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.jiph.2023.08.009" target="_blank">https://dx.doi.org/10.1016/j.jiph.2023.08.009</a></p>2023-11-01T00:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1016/j.jiph.2023.08.009https://figshare.com/articles/journal_contribution/Follow_up_and_comparative_assessment_of_IgG_IgA_and_neutralizing_antibody_responses_to_SARS-CoV-2_between_mRNA-vaccinated_na_ve_and_unvaccinated_naturally_infected_individuals_over_10_months/25101905CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/251019052023-11-01T00:00:00Z
spellingShingle Follow up and comparative assessment of IgG, IgA, and neutralizing antibody responses to SARS-CoV-2 between mRNA-vaccinated naïve and unvaccinated naturally infected individuals over 10 months
Salma Younes (6424865)
Biomedical and clinical sciences
Clinical sciences
COVID-19
MRNA vaccines
Waning
Neutralizing antibodies
Anti-S-RBD-IgG
Anti-S1-IgA
status_str publishedVersion
title Follow up and comparative assessment of IgG, IgA, and neutralizing antibody responses to SARS-CoV-2 between mRNA-vaccinated naïve and unvaccinated naturally infected individuals over 10 months
title_full Follow up and comparative assessment of IgG, IgA, and neutralizing antibody responses to SARS-CoV-2 between mRNA-vaccinated naïve and unvaccinated naturally infected individuals over 10 months
title_fullStr Follow up and comparative assessment of IgG, IgA, and neutralizing antibody responses to SARS-CoV-2 between mRNA-vaccinated naïve and unvaccinated naturally infected individuals over 10 months
title_full_unstemmed Follow up and comparative assessment of IgG, IgA, and neutralizing antibody responses to SARS-CoV-2 between mRNA-vaccinated naïve and unvaccinated naturally infected individuals over 10 months
title_short Follow up and comparative assessment of IgG, IgA, and neutralizing antibody responses to SARS-CoV-2 between mRNA-vaccinated naïve and unvaccinated naturally infected individuals over 10 months
title_sort Follow up and comparative assessment of IgG, IgA, and neutralizing antibody responses to SARS-CoV-2 between mRNA-vaccinated naïve and unvaccinated naturally infected individuals over 10 months
topic Biomedical and clinical sciences
Clinical sciences
COVID-19
MRNA vaccines
Waning
Neutralizing antibodies
Anti-S-RBD-IgG
Anti-S1-IgA